Post-earnings recap
Reported
Wed, Nov 13, 2024
EPS actual
$-0.78
EPS est.
$-0.60
EPS surprise
-30.00%
1-day move
-7.21%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Immunome Inc's disappointing EPS results have led to a 7.21% drop in stock price, reflecting investor concerns about the company's financial health. The lack of revenue information and guidance further adds to uncertainty. Investors will be looking for clarity in future communications from management as the company navigates its challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.78 | N/A | -30.00% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the company's performance this quarter. They highlighted the need for strategic adjustments moving forward.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term strategies despite current setbacks.